Novartis Drug Combo Cuts Pancreatic Tumour Size
24th June 2009 by admin No CommentsA combination of two drugs from Novartis AG (NOVN.VX) cut the size of pancreatic neuroendocrine tumours in more than 80 percent of patients in a mid-stage study, the Swiss group said on Wednesday. Patients who received a once-daily pill Afinitor in combination with Sandostatin LAR had no progression in their disease for a median of [...]